Trelegy Ellipta 100 ug/1 (Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate POWDER) 100 ug/1

Trelegy Ellipta 100 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This powder inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Strength

100 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0887-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trelegy Ellipta 100 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination of fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate works to reduce inflammation and improve airflow in the lungs. This inhaler is often prescribed for individuals who require a combination of a corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-agonist for effective respiratory management.

Side Effects

Common effects of Trelegy Ellipta 100 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience a taste alteration or coughing after inhalation. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

Precautions & Warnings

Trelegy Ellipta 100 ug/1 should be used as directed by a healthcare provider. It is important to follow the proper inhalation technique to ensure effective delivery of the medication. Patients with a history of severe hypersensitivity to any of the components should avoid using this inhaler. Regular monitoring and follow-up are recommended to assess the ongoing need for this medication.

Avoid Interactions

Trelegy Ellipta 100 ug/1 may interact with other medications, including beta-blockers, which can reduce the effectiveness of the beta-agonist component. It is also important to avoid using this inhaler with other long-acting beta-agonists or anticholinergics without medical supervision. Alcohol and certain other substances may also interact with this medication, so it is advisable to discuss all current medications with a healthcare provider.

Frequently Asked Questions

Trelegy Ellipta 100 ug/1 is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Trelegy Ellipta 100 ug/1 is administered via inhalation, typically once daily. Follow the instructions provided by your healthcare provider for proper use.

Common side effects may include throat irritation, headache, dry mouth, taste alteration, and coughing.

Trelegy Ellipta 100 ug/1 may interact with other medications, including beta-blockers. Consult your healthcare provider before combining it with other treatments.

Trelegy Ellipta 100 ug/1 is not suitable for individuals with severe hypersensitivity to any of its components. Always consult a healthcare provider before starting this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.